PL3728271T3 - Związki makrocykliczne do leczenia chorób - Google Patents
Związki makrocykliczne do leczenia choróbInfo
- Publication number
- PL3728271T3 PL3728271T3 PL18893293.3T PL18893293T PL3728271T3 PL 3728271 T3 PL3728271 T3 PL 3728271T3 PL 18893293 T PL18893293 T PL 18893293T PL 3728271 T3 PL3728271 T3 PL 3728271T3
- Authority
- PL
- Poland
- Prior art keywords
- treating diseases
- macrocyclic compounds
- macrocyclic
- compounds
- diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607528P | 2017-12-19 | 2017-12-19 | |
| US201862727124P | 2018-09-05 | 2018-09-05 | |
| US201862779283P | 2018-12-13 | 2018-12-13 | |
| PCT/US2018/066158 WO2019126121A1 (en) | 2017-12-19 | 2018-12-18 | Macrocyclic compounds for treating disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3728271T3 true PL3728271T3 (pl) | 2023-01-23 |
Family
ID=66992951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18893293.3T PL3728271T3 (pl) | 2017-12-19 | 2018-12-18 | Związki makrocykliczne do leczenia chorób |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10745416B2 (pl) |
| EP (2) | EP3728271B1 (pl) |
| JP (2) | JP7194188B2 (pl) |
| KR (1) | KR102814342B1 (pl) |
| CN (1) | CN111511746B (pl) |
| AU (1) | AU2018392332B2 (pl) |
| BR (1) | BR112020012319A2 (pl) |
| CA (1) | CA3083674A1 (pl) |
| CL (1) | CL2020001632A1 (pl) |
| DK (1) | DK3728271T3 (pl) |
| EC (1) | ECSP20033467A (pl) |
| ES (1) | ES2929467T3 (pl) |
| HR (1) | HRP20221502T1 (pl) |
| HU (1) | HUE060711T2 (pl) |
| IL (1) | IL275265B2 (pl) |
| JO (1) | JOP20200152A1 (pl) |
| LT (1) | LT3728271T (pl) |
| MX (1) | MX2020006490A (pl) |
| PE (1) | PE20200937A1 (pl) |
| PH (1) | PH12020550901A1 (pl) |
| PL (1) | PL3728271T3 (pl) |
| PT (1) | PT3728271T (pl) |
| RS (1) | RS63787B1 (pl) |
| SG (1) | SG11202005590PA (pl) |
| SI (1) | SI3728271T1 (pl) |
| SM (1) | SMT202200443T1 (pl) |
| TW (1) | TW201930312A (pl) |
| WO (1) | WO2019126121A1 (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017079140A1 (en) | 2015-11-02 | 2017-05-11 | Blueprint Medicines Corporation | Inhibitors of ret |
| RS62818B1 (sr) | 2017-10-18 | 2022-02-28 | Incyte Corp | Kondenzovani derivati imidazola zamenjeni tercijarnim hidroksi grupama kao inhibitorima pi3k-gamma |
| PL3710438T3 (pl) | 2017-12-19 | 2022-01-31 | Bristol-Myers Squibb Company | Triazolowe kwasy karbamoilocykloheksylowe z n-wiązaniem jako antagoniści lpa |
| RS63787B1 (sr) | 2017-12-19 | 2022-12-30 | Turning Point Therapeutics Inc | Makrociklična jedinjenja za lečenje bolesti |
| JP7422084B2 (ja) | 2018-04-03 | 2024-01-25 | ブループリント メディシンズ コーポレイション | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 |
| EP3833372A4 (en) | 2018-08-10 | 2022-06-08 | Blueprint Medicines Corporation | TREATMENT OF EGFR MUTANT CANCER |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| SG11202104017VA (en) | 2018-10-22 | 2021-05-28 | Esker Therapeutics Inc | Tyk2 inhibitors and uses thereof |
| WO2020257189A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for treating disease |
| CN114025765A (zh) | 2019-06-19 | 2022-02-08 | 特普医药公司 | 巨环激酶抑制剂的多晶型 |
| WO2020257165A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for use in treating disease |
| WO2021027503A1 (zh) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | 三环类化合物、其制备方法、中间体及应用 |
| CA3163735A1 (en) * | 2019-12-03 | 2021-06-10 | Turning Point Therapeutics, Inc. | Macrocycles for use in treating disease |
| WO2021243192A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| CN113754682B (zh) | 2020-06-04 | 2023-01-06 | 赛诺哈勃药业（成都）有限公司 | 具有大环结构的化合物及其用途 |
| CA3188313A1 (en) | 2020-08-05 | 2022-02-10 | C4 Therapeutics, Inc. | Compounds for targeted degradation of ret |
| CN116635076A (zh) * | 2020-12-17 | 2023-08-22 | 荣山医药股份有限公司 | 大环化合物及其用途 |
| US20250002505A1 (en) * | 2021-10-05 | 2025-01-02 | Turning Point Therapeutics, Inc. | Synthesis of macroyclic compounds |
| CN119630675A (zh) * | 2022-07-22 | 2025-03-14 | 南京明德新药研发有限公司 | 含三并环的大环类化合物及其应用 |
| WO2024040131A1 (en) * | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| JP7571173B2 (ja) | 2023-02-24 | 2024-10-22 | キヤノン株式会社 | 撮像装置、撮像装置の制御方法、及びプログラム |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3298885B2 (ja) * | 1993-03-25 | 2002-07-08 | ファルマシア・アンド・アップジョン・カンパニー | ドーパミン作働性活性を有するインドールテトラリン類 |
| BR9404831A (pt) | 1993-12-07 | 1995-08-08 | Lilly Co Eli | Composto,formulação farmacêutica e processo de preparação de um composto |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| AU2002227371B2 (en) | 2000-12-08 | 2007-05-10 | Ortho-Mcneil Pharmaceutical, Inc. | Macroheterocylic compounds useful as kinase inhibitors |
| MX2011002470A (es) | 2008-09-08 | 2011-04-05 | Merck Patent Gmbh | Pirimidinas macrociclicas como inhibidores de aurora cinasa. |
| RS53350B (sr) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze |
| PT2725028T (pt) | 2008-10-22 | 2016-08-31 | Array Biopharma Inc | Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk |
| RU2539568C2 (ru) | 2008-10-31 | 2015-01-20 | Дженентек, Инк. | Пиразолопиримидиновые соединения-ингибиторы jak и способы |
| CA2777664C (en) | 2009-10-13 | 2014-06-10 | Johannes Wilhelmus J. Thuring | Macrocyclic integrase inhibitors |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| WO2011146336A1 (en) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Macrocyclic compounds as trk kinase inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| CA2817785A1 (en) * | 2010-11-19 | 2012-05-24 | Toby Blench | Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| EP2744507A4 (en) | 2011-08-19 | 2015-01-28 | Merck Sharp & Dohme | CRYSTAL FORMS OF AN HCV PROTEASE HEMMER |
| KR20140078710A (ko) | 2011-09-30 | 2014-06-25 | 온코디자인 에스.에이. | 거대고리 flt3 키나제 억제제 |
| DK2822953T5 (en) | 2012-03-06 | 2017-09-11 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| MX347917B (es) | 2012-03-09 | 2017-05-17 | Lexicon Pharmaceuticals Inc | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. |
| AU2013230128B2 (en) | 2012-03-09 | 2017-08-17 | Lexicon Pharmaceuticals, Inc. | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| MX2016009588A (es) | 2014-01-24 | 2017-05-15 | Tp Therapeutics Inc | Macrociclos de diarilo como moduladores de la proteina quinasa. |
| CA2954187C (en) * | 2014-07-21 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Macrocyclic kinase inhibitors and uses thereof |
| CN107735399B (zh) | 2015-07-02 | 2021-01-26 | 特普医药公司 | 作为蛋白质激酶的调节剂的手性二芳基大环 |
| BR112018000297A2 (pt) | 2015-07-06 | 2018-09-04 | Tp Therapeutics Inc | polimorfo de macrociclo de diarila |
| US20180325901A1 (en) | 2015-07-21 | 2018-11-15 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles and uses thereof |
| EP3763693A1 (en) * | 2016-03-03 | 2021-01-13 | Shenzhen TargetRx, Inc. | Macrocycle and composition comprising thereof |
| CN106008531B (zh) * | 2016-05-30 | 2019-01-11 | 上海交通大学 | 多环稠合大环内酰胺类化合物的抗胰腺癌用途 |
| CN109715165A (zh) | 2016-07-28 | 2019-05-03 | Tp生物医药公司 | 巨环激酶抑制剂 |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| PT3658148T (pt) | 2017-07-28 | 2024-08-26 | Turning Point Therapeutics Inc | Compostos macrocíclicos e utilizações dos mesmos |
| RS62818B1 (sr) | 2017-10-18 | 2022-02-28 | Incyte Corp | Kondenzovani derivati imidazola zamenjeni tercijarnim hidroksi grupama kao inhibitorima pi3k-gamma |
| GB201721235D0 (en) | 2017-12-19 | 2018-01-31 | Syngenta Participations Ag | Polymorphs |
| EP3728270A4 (en) * | 2017-12-19 | 2021-06-23 | Turning Point Therapeutics, Inc. | MACROCYCLIC KINASE INHIBITORS AND THEIR USES |
| RS63787B1 (sr) | 2017-12-19 | 2022-12-30 | Turning Point Therapeutics Inc | Makrociklična jedinjenja za lečenje bolesti |
| PL3710438T3 (pl) | 2017-12-19 | 2022-01-31 | Bristol-Myers Squibb Company | Triazolowe kwasy karbamoilocykloheksylowe z n-wiązaniem jako antagoniści lpa |
| WO2019120267A1 (zh) | 2017-12-22 | 2019-06-27 | 成都先导药物开发股份有限公司 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
| DK3783000T3 (da) | 2018-04-18 | 2022-08-01 | Hitgen Inc | Makrocyklisk kinasehæmmer |
-
2018
- 2018-12-18 RS RS20221099A patent/RS63787B1/sr unknown
- 2018-12-18 DK DK18893293.3T patent/DK3728271T3/da active
- 2018-12-18 PE PE2020000787A patent/PE20200937A1/es unknown
- 2018-12-18 JO JOP/2020/0152A patent/JOP20200152A1/ar unknown
- 2018-12-18 EP EP18893293.3A patent/EP3728271B1/en active Active
- 2018-12-18 BR BR112020012319-6A patent/BR112020012319A2/pt not_active IP Right Cessation
- 2018-12-18 CA CA3083674A patent/CA3083674A1/en active Pending
- 2018-12-18 EP EP22191652.1A patent/EP4151641A1/en active Pending
- 2018-12-18 LT LTEPPCT/US2018/066158T patent/LT3728271T/lt unknown
- 2018-12-18 HU HUE18893293A patent/HUE060711T2/hu unknown
- 2018-12-18 WO PCT/US2018/066158 patent/WO2019126121A1/en not_active Ceased
- 2018-12-18 ES ES18893293T patent/ES2929467T3/es active Active
- 2018-12-18 KR KR1020207017739A patent/KR102814342B1/ko active Active
- 2018-12-18 PL PL18893293.3T patent/PL3728271T3/pl unknown
- 2018-12-18 HR HRP20221502TT patent/HRP20221502T1/hr unknown
- 2018-12-18 SG SG11202005590PA patent/SG11202005590PA/en unknown
- 2018-12-18 SM SM20220443T patent/SMT202200443T1/it unknown
- 2018-12-18 AU AU2018392332A patent/AU2018392332B2/en not_active Ceased
- 2018-12-18 PT PT188932933T patent/PT3728271T/pt unknown
- 2018-12-18 JP JP2020533594A patent/JP7194188B2/ja active Active
- 2018-12-18 SI SI201830779T patent/SI3728271T1/sl unknown
- 2018-12-18 MX MX2020006490A patent/MX2020006490A/es unknown
- 2018-12-18 CN CN201880082563.6A patent/CN111511746B/zh active Active
- 2018-12-19 TW TW107145927A patent/TW201930312A/zh unknown
-
2020
- 2020-01-30 US US16/777,717 patent/US10745416B2/en active Active
- 2020-05-05 US US16/866,983 patent/US11286265B2/en active Active
- 2020-06-10 IL IL275265A patent/IL275265B2/en unknown
- 2020-06-15 PH PH12020550901A patent/PH12020550901A1/en unknown
- 2020-06-17 CL CL2020001632A patent/CL2020001632A1/es unknown
- 2020-06-19 EC ECSENADI202033467A patent/ECSP20033467A/es unknown
-
2022
- 2022-02-14 US US17/670,665 patent/US20220306652A1/en not_active Abandoned
- 2022-12-09 JP JP2022197141A patent/JP2023027237A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3728271T3 (pl) | Związki makrocykliczne do leczenia chorób | |
| SG11201705093UA (en) | Composition for treating il-6-related diseases | |
| SMT201900172T1 (it) | Ammino triazoli sostituiti utili come inibitori della chitinasi umana | |
| IL249229B (en) | Compounds for the treatment of brain cancer | |
| HUE050567T2 (hu) | Triciklusos heterociklusok rák kezelésére | |
| IL251790B (en) | Compounds include thiazole for the treatment of culture diseases | |
| GB201709402D0 (en) | Compounds for treating t-pll | |
| GB201716942D0 (en) | Therapeutic compounds | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| ZA201906047B (en) | Compounds for treating tuberculosis | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
| ZA201704589B (en) | Compounds for the treatment of cancer | |
| EP3261635A4 (en) | Compounds for treating ocular diseases | |
| GB201420348D0 (en) | Compounds for treating neurodegenerative diseases | |
| HK40036156A (en) | Macrocyclic compounds for treating disease | |
| ZA201805215B (en) | Preparation for nasal-nasopharyngeal treatment | |
| GB201715210D0 (en) | Macrocyclic compounds | |
| GB201712390D0 (en) | Therapeutic compounds | |
| GB201712388D0 (en) | Therapeutic compounds | |
| GB201712392D0 (en) | Therapeutic compounds | |
| GB201712393D0 (en) | Therapeutic compounds | |
| GB201712394D0 (en) | Therapeutic compounds | |
| GB201712395D0 (en) | Therapeutic compounds | |
| EP3354271A4 (en) | Agent for treating arthrological diseases |